Polymeric Lipid Hybrid Nanoparticles: Properties and Therapeutic Applications

Jose, Cyril; Amra, Kesrin; Bhavsar, Chintan; Momin, Munira; Omri, Abdelwahab

doi:10.1615/critrevtherdrugcarriersyst.2018024751

Cited by 32 publications

(14 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lipid-polymer hybrid nanoparticles (LP-NPs) are novel hybrid materials that have gained a lot of attention in recent years and they have been developed to achieve an improved therapeutic effect with the least adverse effect [ 15 , 16 ]. Due to their particular core–shell structure, LP-NPs exhibit good storage stability, controlled release profiles due to the polymer core, enhanced therapeutic potency, and biocompatibility because of the lipid–PEG and lipid layers [ 17 ].…”

Section: Introductionmentioning

confidence: 99%

Development of Sustained Release Baricitinib Loaded Lipid-Polymer Hybrid Nanoparticles with Improved Oral Bioavailability

et al. 2021

View full text Add to dashboard Cite

Baricitinib (BTB) is an orally administered Janus kinase inhibitor, therapeutically used for the treatment of rheumatoid arthritis. Recently it has also been approved for the treatment of COVID-19 infection. In this study, four different BTB-loaded lipids (stearin)-polymer (Poly(d,l-lactide-co-glycolide)) hybrid nanoparticles (B-PLN1 to B-PLN4) were prepared by the single-step nanoprecipitation method. Next, they were characterised in terms of physicochemical properties such as particle size, zeta potential (ζP), polydispersity index (PDI), entrapment efficiency (EE) and drug loading (DL). Based on preliminary evaluation, the B-PLN4 was regarded as the optimised formulation with particle size (272 ± 7.6 nm), PDI (0.225), ζP (−36.5 ± 3.1 mV), %EE (71.6 ± 1.5%) and %DL (2.87 ± 0.42%). This formulation (B-PLN4) was further assessed concerning morphology, in vitro release, and in vivo pharmacokinetic studies in rats. The in vitro release profile exhibited a sustained release pattern well-fitted by the Korsmeyer–Peppas kinetic model (R2 = 0.879). The in vivo pharmacokinetic data showed an enhancement (2.92 times more) in bioavailability in comparison to the normal suspension of pure BTB. These data concluded that the formulated lipid-polymer hybrid nanoparticles could be a promising drug delivery option to enhance the bioavailability of BTB. Overall, this study provides a scientific basis for future studies on the entrapment efficiency of lipid-polymer hybrid systems as promising carriers for overcoming pharmacokinetic limitations.

show abstract

Section: Introductionmentioning

confidence: 99%

Development of Sustained Release Baricitinib Loaded Lipid-Polymer Hybrid Nanoparticles with Improved Oral Bioavailability

et al. 2021

View full text Add to dashboard Cite

show abstract

“…For site-specific conjugation of antibody onto nanoparticles, PNs were first shelled with a layer of maleimide-functionalized lipid using a co-extrusion technique 17 . All lipids—1,2-dipalmitoyl- sn -glycero-3-phosphocholine (DPPC), 1,2-dipalmitoyl- sn -glycero-3-phosphorylglycerol (DPPG), 1,2-distearoyl- sn -glycero-3-phosphoethanolamine- N -[maleimide(polyethylene glycol)-2000] (ammonium salt, DSPE-malPEG 2000 ), fluorescein isothiocyanate-conjugated PEG lipid (DSPE-PEG 2000 -FITC), cyanine 5-conjugated PEG lipid (DSPE-PEG 2000 -Cy5)—were purchased from Avanti Polar Lipids (Birmingham, AL, USA).…”

Section: Methodsmentioning

confidence: 99%

Molecular engineering of antibodies for site-specific conjugation to lipid polydopamine hybrid nanoparticles

Yang

Shim

et al. 2020

Acta Pharmaceutica Sinica B

View full text Add to dashboard Cite

Conjugation of antibodies to nanoparticles allows specific cancer targeting, but conventional conjugation methods generate heterogeneous conjugations that cannot guarantee the optimal orientation and functionality of the conjugated antibody. Here, a molecular engineering technique was used for site-specific conjugation of antibodies to nanoparticles. We designed an anti-claudin 3 (CLDN3) antibody containing a single cysteine residue, h4G3cys, then linked it to the maleimide group of lipid polydopamine hybrid nanoparticles (LPNs). Because of their negatively charged lipid coating, LPNs showed high colloidal stability and provided a functional surface for site-specific conjugation of h4G3cys. The activity of h4G3cys was tested by measuring the binding of h4G3cys-conjugated LPNs (C-LPNs) to CLDN3-positive tumor cells and assessing its subsequent photothermal effects. C-LPNsspecifically recognized CLDN3-overexpressing T47D breast cancer cells but not CLDN3-negative Hs578T breast cancer cells. High binding of C-LPNs to CLDN3-overexpressing T47D cells resulted in significantly higher temperature generation upon NIR irradiation and potent anticancer photothermal efficacy. Consistent with this, intravenous injection of C-LPNsin a T47D xenograft mouse model followed by NIR irradiation caused remarkable tumor ablation compared with other treatments through high temperature increases. Our results establish an accurate antibody-linking method and demonstrate the possibility of developing therapeutics using antibody-guided nanoparticles.

show abstract

“…Although liposomes have many intrinsic advantages, poor stability and low drug loading capacity of conventional liposomes limit their efficacy, thus needing further optimization 8 , 9 , 10 . Recently, hybrid lipid‒nanoparticle complexes (HLNCs) have emerged as a new generation of drug delivery systems 11 , 12 , 13 . These hybrids are engineered to integrate the excellent properties of nanoparticles, such as high stability and ease of functionalization, with good biocompatibility and low toxicity of liposomes.…”

Section: Introductionmentioning

confidence: 99%

A mitochondria-targeting lipid–small molecule hybrid nanoparticle for imaging and therapy in an orthotopic glioma model

Tang

Lin

Ramachandran

et al. 2022

Acta Pharmaceutica Sinica B

View full text Add to dashboard Cite

Polymeric Lipid Hybrid Nanoparticles: Properties and Therapeutic Applications

Cited by 32 publications

References 56 publications

Development of Sustained Release Baricitinib Loaded Lipid-Polymer Hybrid Nanoparticles with Improved Oral Bioavailability

Development of Sustained Release Baricitinib Loaded Lipid-Polymer Hybrid Nanoparticles with Improved Oral Bioavailability

Molecular engineering of antibodies for site-specific conjugation to lipid polydopamine hybrid nanoparticles

A mitochondria-targeting lipid–small molecule hybrid nanoparticle for imaging and therapy in an orthotopic glioma model

Contact Info

Product

Resources

About